Key hire
Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment
Glyscend reports its GLY-200 Phase 1 trial finished safely in healthy volunteers, with Phase 2 planned, and appoints Mark Fineman as Chief Development Officer to lead its metabolic disease programs.